Hudson Bay Capital Management LP Boosts Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Hudson Bay Capital Management LP lifted its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 43.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 308,100 shares of the biotechnology company's stock after purchasing an additional 93,100 shares during the quarter. Hudson Bay Capital Management LP owned about 0.62% of REGENXBIO worth $2,382,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its position in REGENXBIO by 67.0% during the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock worth $31,975,000 after acquiring an additional 1,659,206 shares during the period. Adage Capital Partners GP L.L.C. acquired a new stake in REGENXBIO during the 4th quarter worth about $3,865,000. Norges Bank acquired a new stake in REGENXBIO during the 4th quarter worth about $3,474,000. Cubist Systematic Strategies LLC acquired a new stake in REGENXBIO during the 4th quarter worth about $2,793,000. Finally, Voss Capital LP acquired a new stake in REGENXBIO during the 4th quarter worth about $2,573,000. Institutional investors and hedge funds own 88.08% of the company's stock.

Insider Buying and Selling

In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the business's stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the sale, the director now directly owns 475,103 shares in the company, valued at approximately $3,758,064.73. The trade was a 4.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.79% of the stock is currently owned by insiders.

REGENXBIO Price Performance

NASDAQ RGNX traded up $0.25 during trading hours on Friday, reaching $8.89. The company's stock had a trading volume of 825,125 shares, compared to its average volume of 866,997. The firm has a market capitalization of $445.92 million, a price-to-earnings ratio of -1.77 and a beta of 1.11. REGENXBIO Inc. has a 1-year low of $5.04 and a 1-year high of $16.25. The company's 50-day moving average is $7.54 and its two-hundred day moving average is $7.98.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). The business had revenue of $89.01 million during the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Equities analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have commented on RGNX shares. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, March 20th. Leerink Partners set a $24.00 price objective on REGENXBIO in a report on Tuesday, March 18th. The Goldman Sachs Group decreased their price objective on REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Morgan Stanley boosted their price objective on REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday, March 14th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, REGENXBIO presently has an average rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.